Incretin-based therapy for MASH: are two better than one?

References

[1] Ho GJK,Sasikumar NA.High global prevalence of steatotic liver disease and associated subtypes: a meta-analysis.Clin Gastroenterol Hepatol2025;23:2423-32.e1

[2] Tilg H,Stefan N.Metabolic dysfunction-associated steatotic liver disease in adults: a review.JAMA2026;335:163-74

[3] Amangurbanova M,Noureddin N.A prospective study on the prevalence of MASLD in patients with type 2 diabetes and hyperferritinaemia.Aliment Pharmacol Ther2025;61:456-64

[4] Liu J,Gao B,Cao Y.Resmetirom, the first FDA-approved drug for MASH: from drug discovery and action mechanisms to clinical trials.Arch Pharm Res2025;48:1299-313

[5] Harrison SA, Bedossa P, Guy CD, et al.; MAESTRO-NASH Investigators. A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis. N Engl J Med. 2024;390:497-509.

[6] Brouwers B,Tang Y,Glass LC.Incretin-based investigational therapies for the treatment of MASLD/MASH.Diabetes Res Clin Pract2024;211:111675

[7] Sanyal AJ, Newsome PN, Kliers I, et al.; ESSENCE Study Group. Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis. N Engl J Med. 2025;392:2089-99.

[8] Loomba R, Hartman ML, Lawitz EJ, et al.; SYNERGY-NASH Investigators. Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis. N Engl J Med. 2024;391:299-310.

[9] Sanyal AJ, Bedossa P, Fraessdorf M, et al.; 1404-0043 Trial Investigators. A phase 2 randomized trial of survodutide in MASH and fibrosis. N Engl J Med. 2024;391:311-9.

[10] Noureddin M,Loomba R.Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study.Lancet2025;406:2644-55